Quick Answer
GRI Bio, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
GRI Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | $0.00 -100.0% |
$100.0K |
| Revenue (ASC 606) | — | — | — | — | $0.00 -100.0% |
$100.0K |
| Net Income | -$11.96M -45.7% |
-$8.21M +37.0% |
-$13.04M -305.3% |
-$3.22M +65.4% |
-$9.30M -92.9% |
-$4.82M |
| Diluted EPS | -$121.80 +92.1% |
-$1545.55 +69.2% |
-$5018.09 -20012.6% |
-$24.95 -1657.0% |
-$1.42 -32.7% |
-$1.07 |
| Total Assets | $8.67M +51.0% |
$5.74M +94.1% |
$2.96M +671.8% |
$383.0K -95.4% |
$8.34M +772.8% |
$955.0K |
| Cash and Equivalents | $8.23M +63.7% |
$5.03M +178.1% |
$1.81M +19988.9% |
$9.0K -99.8% |
$3.70M +3296.3% |
$109.0K |
| Stockholders Equity | $6.01M +49.0% |
$4.03M +1456.8% |
$259.0K +115.9% |
-$1.62M +66.5% |
-$4.85M -233.4% |
-$1.45M -145.2% |
| R&D Expense | $6.82M +81.0% |
$3.77M +16.6% |
$3.23M +1235.5% |
$242.0K -95.3% |
$5.19M +39.9% |
$3.71M |
| Operating Income | -$11.98M -45.4% |
-$8.23M +27.7% |
-$11.39M -408.6% |
-$2.24M +75.8% |
-$9.26M -93.4% |
-$4.79M |
| Shares Outstanding | 497,693 +2551.8% |
18,768 -95.6% |
422,333 +195.7% |
142,820 -97.9% |
6.81M +51.2% |
4.51M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2022 | $0.00 | — | — |
| Revenue (ASC 606) | March 31, 2022 | $0.00 | — | — |
| Net Income | September 30, 2025 | -$3.36M | -58.2% | -16.1% |
| Diluted EPS | September 30, 2025 | -$1.28 | +88.8% | +2.3% |
| Total Assets | September 30, 2025 | $4.78M | -12.4% | -15.7% |
| Cash and Equivalents | September 30, 2025 | $4.05M | -14.6% | -20.8% |
| Stockholders Equity | September 30, 2025 | $1.99M | -45.5% | -40.0% |
| R&D Expense | September 30, 2025 | $1.77M | +57.2% | -5.9% |
| Operating Income | September 30, 2025 | -$3.37M | -58.0% | -16.2% |
| Shares Outstanding | September 30, 2025 | 3.27M | -34.9% | +30.9% |
- GRI Bio, Inc. reported Total Revenue of $0.00 for fiscal year 2021.
- GRI Bio, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- GRI Bio, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2021.
- GRI Bio, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- GRI Bio, Inc. reported Net Income of -$11.96 million for fiscal year 2025.
- GRI Bio, Inc. showed a decrease of -45.7% in Net Income compared to the prior fiscal year.
- GRI Bio, Inc. reported Diluted EPS of $121.80 per share (loss) for fiscal year 2025.
- GRI Bio, Inc. showed an increase of +92.1% in Diluted EPS compared to the prior fiscal year.
- GRI Bio, Inc. reported Total Assets of $8.67 million for fiscal year 2025.
- GRI Bio, Inc. showed an increase of +51.0% in Total Assets compared to the prior fiscal year.
- GRI Bio, Inc. reported Cash and Equivalents of $8.23 million for fiscal year 2025.
- GRI Bio, Inc. showed an increase of +63.7% in Cash and Equivalents compared to the prior fiscal year.
- GRI Bio, Inc. reported Stockholders Equity of $6.01 million for fiscal year 2025.
- GRI Bio, Inc. showed an increase of +49.0% in Stockholders Equity compared to the prior fiscal year.
- GRI Bio, Inc. reported R&D Expense of $6.82 million for fiscal year 2025.
- GRI Bio, Inc. showed an increase of +81.0% in R&D Expense compared to the prior fiscal year.
- GRI Bio, Inc. reported Operating Income of -$11.98 million for fiscal year 2025.
- GRI Bio, Inc. showed a decrease of -45.4% in Operating Income compared to the prior fiscal year.
- GRI Bio, Inc. reported Shares Outstanding of 497.7 thousand shares for fiscal year 2025.
- GRI Bio, Inc. showed an increase of +2551.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: